NASDAQ: INCRIntercure Ltd Stock
$1.38+0.01 (+0.73%)
Updated Apr 17, 2025
INCR Price
$1.38
Fair Value Price
N/A
Market Cap
$62.66M
52 Week Low
$1.17
52 Week High
$3.72
P/E
-3.55x
P/B
0.51x
P/S
1.27x
PEG
N/A
Dividend Yield
N/A
Revenue
$73.30M
Earnings
-$17.41M
Gross Margin
28.9%
Operating Margin
-11.39%
Profit Margin
-24.1%
Debt to Equity
0.61
Operating Cash Flow
N/A
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INCR Overview
Intercure Limited produces and distributes medical cannabis products in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed industries. InterCure was incorporated in 1994 and is headquartered in Herzliya, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INCR's potential to beat the market
- INCR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
INCR
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important INCR news, forecast changes, insider trades & much more!
INCR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INCR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INCR is good value based on its book value relative to its share price (0.51x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.99x)
P/B vs Industry Valuation
INCR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INCR due diligence checks available for Premium users.
Valuation
INCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.55x
Industry
20.48x
Market
27.98x
INCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
1.99x
INCR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INCR's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
INCR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$196.5M
Liabilities
$73.9M
Debt to equity
0.61
INCR's short-term assets ($99.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INCR's short-term assets ($99.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
INCR vs Pharmaceutical Stocks
Intercure Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.